Endocrine Abstracts

Background: Plasminogen activator inhibitor-1 (PAI-1) refers to group of is a serine protein inhibitors. It inhibits fibrinolysis and contributes to angiogenesis and atherogenesis processes. 4G/5G polymorphism was found to be associated with increased risk for cardiovascular diseases. It was of special interest to study PAI-1 polymorphism in patients with diabetes.

Aim: Aim to study PAI-1 polymorphism in patients with type 2 diabetes (T2D) and concomitant coronary heart disease (CHD).

Materials and methods: 48 patients were included: group 1–20 almost healthy person, group 2–13 patients with T2D, group 3–15 patients with T2D and CHD. Patients were under 60 years old, patients with T2D were compensated by HbA1c (6.5+1.2% in group 2 and 6.5+0.6% in group three correspondingly). Polymorphic variant of PAI-1 was determined by polymerase chain reaction (PCR).

Results and discussion: 4G/5G polymorphism was statistically significant more frequent in patients with T2D and concomitant CHD (ten of the 15, 66,7%) compared to patients with diabetes (three of the 13, 23.1%) (P<0.05) and almost healthy person (ten of the 20, 50%) (P<0.05). In group 2 4G/4G polymorphism was recorded in five patients (38.5%) that was more frequent compared to group 3 (two of 15, 13.3%) (P<0.05), and six of 20 in controls (30%). There was no difference in frequencies between groups in 5G/5G polymorphism (three patients (15%) in group 1, four patients (30.8%) in group 2 and three patients (20%) in group 4).

Conclusion: 4G/5G polymorphism is associated with CHD in patients with type 2 diabetes. 4G/4G polymorphism is supposed to have protective role in relation to macrovascular complication in diabetic patients.